(NASDAQ: SPRO) Spero Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.05%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.95%.
Spero Therapeutics's earnings in 2026 is -$29,513,000.On average, 5 Wall Street analysts forecast SPRO's earnings for 2026 to be -$44,176,202, with the lowest SPRO earnings forecast at -$77,655,028, and the highest SPRO earnings forecast at -$17,741,564. On average, 5 Wall Street analysts forecast SPRO's earnings for 2027 to be -$23,573,848, with the lowest SPRO earnings forecast at -$55,957,300, and the highest SPRO earnings forecast at $40,989,130.
In 2028, SPRO is forecast to generate -$61,807,063 in earnings, with the lowest earnings forecast at -$59,383,257 and the highest earnings forecast at -$63,624,918.